Cognition Therapeutics to Present CT1812 Data, Initiate Late-Stage DLB Psychosis Study on April 13
Cognition Therapeutics will present progress on its lead candidate zervimesine (CT1812) for Alzheimer’s and dementia with Lewy bodies at the 25th Annual Needham Virtual Healthcare Conference on April 13 at 3:00 p.m. ET. Based on strong Phase 2 SHIMMER results in DLB, the company plans a late-stage clinical trial for DLB psychosis.
1. Upcoming Conference Presentation
At the 25th Annual Needham Virtual Healthcare Conference on April 13 at 3:00 p.m. ET, Cognition Therapeutics’ president and CEO Lisa Ricciardi will deliver a presentation on the company’s development programs for Alzheimer’s disease and dementia with Lewy bodies via live webcast and archived replay available for 90 days.
2. Progress on Zervimesine (CT1812)
The company’s lead candidate zervimesine (CT1812) has shown strong efficacy signals in the Phase 2 SHIMMER study in DLB and completed Phase 2 trials in mild-to-moderate Alzheimer’s disease and geographic atrophy, prompting plans for a late-stage clinical trial targeting DLB psychosis.
3. Clinical Pipeline and Funding
Cognition Therapeutics has secured nearly $200 million in National Institutes of Health and foundation grants to support ongoing research across indications including Parkinson’s and geographic atrophy, and is currently enrolling patients in the Phase 2 START study for mild cognitive impairment and early Alzheimer’s disease.